RGNX vs. CRGX, HUMA, PRME, MESO, RLAY, KYTX, HLVX, PROK, EXAI, and ITOS Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include CARGO Therapeutics (CRGX), Humacyte (HUMA), Prime Medicine (PRME), Mesoblast (MESO), Relay Therapeutics (RLAY), Kyverna Therapeutics (KYTX), HilleVax (HLVX), ProKidney (PROK), Exscientia (EXAI), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry.
CARGO Therapeutics (NASDAQ:CRGX ) and REGENXBIO (NASDAQ:RGNX ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
CARGO Therapeutics has higher earnings, but lower revenue than REGENXBIO.
93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 1.4% of CARGO Therapeutics shares are owned by company insiders. Comparatively, 13.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
CARGO Therapeutics has a net margin of 0.00% compared to CARGO Therapeutics' net margin of -299.96%. REGENXBIO's return on equity of 0.00% beat CARGO Therapeutics' return on equity.
In the previous week, REGENXBIO had 8 more articles in the media than CARGO Therapeutics. MarketBeat recorded 17 mentions for REGENXBIO and 9 mentions for CARGO Therapeutics. REGENXBIO's average media sentiment score of 0.50 beat CARGO Therapeutics' score of 0.40 indicating that CARGO Therapeutics is being referred to more favorably in the media.
REGENXBIO received 418 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CARGO Therapeutics an outperform vote while only 65.84% of users gave REGENXBIO an outperform vote.
CARGO Therapeutics presently has a consensus target price of $29.00, suggesting a potential upside of 42.02%. REGENXBIO has a consensus target price of $38.64, suggesting a potential upside of 141.63%. Given CARGO Therapeutics' higher possible upside, analysts clearly believe REGENXBIO is more favorable than CARGO Therapeutics.
Summary CARGO Therapeutics beats REGENXBIO on 8 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
REGENXBIO Competitors List
Related Companies and Tools
